Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feng Han Gan Mao Ke Li is a Traditional Chinese Medicine (TCM) granule formulation developed and manufactured by Shandong Kongfu Pharmaceutical. It is specifically indicated for the treatment of the "wind-cold" type of common cold, which is characterized by symptoms such as aversion to cold, fever without sweating, headache, nasal congestion, runny nose, and cough with thin white phlegm. The formulation is a complex mixture of herbal extracts, typically including Ephedra (麻黄), Pueraria (葛根), and Perilla leaf (紫苏叶), which work synergistically to induce diaphoresis, dispel cold, and ventilate the lungs. Pharmacologically, the product exhibits antipyretic, anti-inflammatory, and antitussive properties, partly mediated by adrenergic receptor agonism from its ephedrine content. It is an approved pharmaceutical product in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on feng han gan mao ke li.